Home About us Current issue Back issues Submission Instructions Advertise Contact Login   

Search Article 
  
Advanced search 
 
Saudi Journal of Kidney Diseases and Transplantation
Users online: 2113 Home Bookmark this page Print this page Email this page Small font sizeDefault font size Increase font size 


 
ORIGINAL ARTICLE Table of Contents   
Year : 2005  |  Volume : 16  |  Issue : 1  |  Page : 23-28
Mycophenolate Mofetil (MMF) Efficacy in Glomerulonephritis (GN), a Retrospective Analysis


King Fahad National Guard Hospital, Riyadh, Saudi Arabia

Correspondence Address:
Junaid I Qureshi
Nephrology, Hypertension & Renal Transplant Division 1531, King Fahad National Guard Hospital, P.O. Box 22490, Riyadh 11426
Saudi Arabia
Login to access the Email id


PMID: 18209455

Rights and Permissions

Mycophenolate Mofetil MMF has been widely used in post-transplant immunosuppression. Its role is emerging in GN. MMF demonstrated promising results compared with cyclosphosphamide in stage IV lupus nephritis, in a recently published trial. It has been found to have a wide safety profile, with mostly gastroinetestinal side effects, which can be avoided through titration. Its action is through inhibition of the enzyme IMDPH (ionosine monophosphate dehydrogenase), leading to purine antagonism and inhibition of lymphocytes. We were aiming to demonstrate the efficacy of MMF in our GN population. In this study, we reviewed 17 patients who received MMF (dose - 1 gm po bid) for the past year. They were only included if it was given for the management of resistant primary glomerulonephritis. Complete remission has been defined as proteinuria of less than 0.5 g/day and partial remission as a reduction of proteinuria < 50% of starting MMF therapy; all 17 MMF therapy patients uniformly achieved good BP (< 140/80) control. MMF was used for a minimum of 1 year and a maximum of 2 years. The results indicate that 7 patients (41%) had a partial remission to MMF. This group was composed of 2 membranous GN, 2 lupus GN (stage IV and stage V) and two with FSGS (1 with single kidney not biopsied) and one with MPGN. Five of 17 (29%) achieved complete remission and this group consisted of 1 membranous GN, 2 lupus GN (type IV and membranous), one FSGS and one with MPGN. Four of 17 (23%) were non-responders to therapy. This group articles.aspx? id=41 to side effects. We conclude that the MMF appears to be an effective alternate treatment modality in resistant membranous GN, lupus nephritis (type IV and V) and possibly MPGN, and to a lesser extent in resistant FSGS. Further prospective data may demonstrate the efficacy of MMF in GN.


[FULL TEXT] [PDF]*
Print this article  Email this article
    

  Similar in PUBMED
    Search Pubmed for
    Search in Google Scholar for
  Related articles
   Citation Manager
  Access Statistics
   Reader Comments
   Email Alert *
   Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed3813    
    Printed108    
    Emailed0    
    PDF Downloaded641    
    Comments [Add]    

Recommend this journal